Association of Age and Serum Anti-Mullerian Hormone level with Serum FSH, LH, and Estradiol

Sultana R¹, Hossain MM², Fatema P³

¹Dr. Rumana Sultana, Assistant Professor, Department of Gynecology, Dhaka Medical College Hospital, Dhaka, Bangladesh

²Dr. Mohammad. Monir Hossian, Assistant Professor, Department of Pediatrics, Sir Salimullah Medical College & Mitford Hospital, Dhaka, Bangladesh

³Prof. Parveen Fatima, Ex. Professor and Department Head, Department of Gynecology and Obstetrics, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh Comesmonding Authors Dr. Pumang Sultang, Dhaka, Medical College

Corresponding Author: Dr. Rumana Sultana, Dhaka Medical College

Abstract

Introduction: Infertility affects approximately 10% to 15% of reproductive-aged couples. The number of goodquality oocytes remaining in the ovaries is referred to as ovarian reserve. As a woman ages, her ovarian reserve decreases, owing primarily to the apoptotic death of primordial follicles. Serum AMH levels are being investigated as a potential testing method for determining ovarian reserve. Other defining biomarkers of fertility include serum FSH, LH, and estradiol. The current study was designed to look for any possible link between patients' ages and these biomarkers.

Aim of the study: The aim of the study was to determine the possible association between patients' age and Serum AMH with serum FSH, LH, Estradiol

Methods: This cross-sectional observational study was conducted at the Department of Obstetrics and Gynaecology, Infertility Unit, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh. The study duration was 14 months, from October 2011 to December 2012. The present study was conducted with 86 women of the reproductive age group with subfertility.

Result: With increasing age, there was a gradual linear decline in AMH. The mean value of FSH and LH increased more gradually in the older age groups of 40-45 years than in the younger age groups of 21-30 years. The mean BMI levels were nearly identical across all age groups, with no discernible differences. The difference in AMH levels was statistically significant across age groups. There was a statistically significant negative correlation between age and serum AMH, but a significant positive correlation between FSH and age. A significant negative correlation was found between the basal level of serum AMH and serum FSH, as well as a non-significant positive correlation.

Conclusion: Serum AMH level decreases with age. Serum AMH was found to be negatively correlated with age, while serum FSH was found to be positively correlated with age. Age had a weak positive correlation with LH and a very weak negative correlation with estradiol, neither of which was statistically significant. Serum AMH and FSH had a significant inverse relationship. There was also a significant difference in mean serum AMH levels between age groups.

Keywords: Fertility, Follicle, Ovarian, Diminishing, Subfertility, Serum AMH, Serum FSH

| Date of Submission: 15-11-2022 | Date of Acceptance: 01-12-2022 |
|--------------------------------|--------------------------------|
| | |

I. Introduction

Childlessness is a major life event. According to population-based studies, 10-15% of couples in the Western world are affected by infertility.^{[1],[2]} Due to women's delayed marriage and childbearing for their carrier, infertility is emerging as a larger conjugal problem. According to recent studies, infertility affects approximately 15-20% of reproductive-aged couples.^[3] Childlessness can be a tragedy for a married couple, particularly for the women, and can cause marital discord as well as personal unhappiness and illness.^[4] The main etiological factor in a series of infertile marriages is found among the female population in approximately 40% of cases, and the absence of ovulation or infrequent ovulation is seen in one-fifth of all women with infertility.^{[4],[5]} The number and quality of oocytes available to produce a dominant follicle late in the follicular phase of the menstrual cycle at any given age are referred to as ovarian reserve.^[6] Diminished ovarian reserve describes a group of patients of any age whose ovaries and the eggs contained within have a significantly reduced ability to produce pregnancies. Infertility is frequently caused by a decrease in ovarian reserve (DOR) or function. DOR has been linked to a poor response to ovarian stimulation, a lower number of oocyte retrieval

during the IVF cycle, lower pregnancy rates after ART cycles, a higher likelihood of cycle cancellation, as well as higher miscarriage and aneuploidy rates.^[7] Age >35 years, previous ovarian surgery, single ovary, unexplained infertility, and a history of poor stimulation with injectable ovulation drugs are all known risk factors for DOR.^[8] AMH is a dimeric glycoprotein composed of two monomers linked together by a disulfide bond. The 72-kD molecule is a member of the superfamily of transforming growth factors, which regulates tissue growth and differentiation.^[9] AMH is produced by Sertoli cells during fetal sex differentiation in males, where it retards Mullerian duct development.^[10] AMH (also known as Mullerian Inhibiting Substance) is produced postnatally in the granulosa cells of early-developing ovarian follicles in the female population and appears to be capable of inhibiting the initiation of primordial follicle growth and FSH-induced follicle growth.^[11] When follicles progress from the primordial to the primary stage, AMH production begins and continues until the follicles reach the antral stages with a diameter of 2-6mm. The preantral and small antral stages of follicle development produce the most AMH.^{[12]-[14]} As the follicle grows larger, production decreases and then stops. AMH is rarely produced in follicles that are larger than 8mm in diameter. As a result, the levels remain constant, and the AMH test can be performed at any point during a woman's cycle. Women with many small follicles, such as those with polycystic ovaries, have high AMH hormone levels, whereas women with few remaining follicles and those nearing menopause have low anti-Mullerian hormone levels.^[15] Because human female serum contains measurable amounts of AMH throughout the reproductive life span,^[9] and because AMH is only produced in growing ovarian follicles, serum level may be used as a marker for ovarian reserve, representing the quality and quantity of the ovarian follicle pool.^[16] Furthermore, serum AMH correlates negatively with age and positively with antral follicle count at ultrasound.^{[17],[18]} Furthermore, determining serum AMH levels in patients with premature ovarian failure (POF) can aid in the evaluation of follicle persistence and possibly fertility potential, and in some patients, it may aid in clarifying the mechanism of ovarian dysfunction.^[19] In Bangladesh, subfertility is now emerging as a critical problem. A significant percentage of patients are attending infertility outdoors and seeking treatment. The present study was conducted to determine the possible correlation of serum AMH and patients with other fertility biomarkers like serum FSH, LH, and Estradiol.

II. Objective

General Objective

• To determine the possible association between patients' age and serum FSH, LH, Estradiol

• To determine the possible association between serum AMH levels and serum FSH, LH, and estradiol

III. Methods

This cross-sectional observational study was conducted at the Department of Obstetrics and Gynaecology, Infertility Unit, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh. The study duration was 14 months, from October 2011 to December 2012. The current study included 86 women of reproductive age who were experiencing infertility. The samples were collected from the 86 study population using a purposive sampling technique. The study participants were chosen based on the inclusion and exclusion criteria. Each participant provided informed written consent, and the study hospital's ethical review committee granted ethical approval. A structured questionnaire was created that included all variables of interest such as age, educational status, occupational status, duration of subfertility, marital history, previous obstetric history such as parity, and the number of living children, a probable cause of subfertility. Anthropometric data, drug history, medical and surgical history, and relevant investigation were also included in the questionnaire. The questionnaire was finalized. All previous investigation reports were thoroughly reviewed to determine the approximate cause of infertility. Following the aseptic procedure, blood samples for the assessment of FSH, LH, Estradiol, and AMH were obtained by venipuncture from patients who met the inclusion and exclusion criteria on days 2-3 of the spontaneous menstrual cycle.

Inclusion Criteria

- Women aged between 21-45 years
- Bangladeshi women diagnosed with subfertility
- Presence of both ovaries
- Patients who had given consent to participate in the study.

Exclusion Criteria

• Women older than 45 years of age

- Women who had surgery in one or both ovaries.
- Women receiving anti-cancer drugs
- Subfertility due to Turner's Syndrome, an Autoimmune disease.
- Exclude those affected with other chronic diseases etc.

IV. Results

Table 1: Distribution of biomarkers at basal level (D3) among subfertile patients (n=86)

| Variables | Mean | ±SD |
|------------------------------------|-------------|-------|
| AMH (Anti-Mullerian hormone) | 2.72ng/ml | ±3.61 |
| FSH (Follicle-stimulating hormone) | 6.20 miu/ml | ±3.94 |
| LH (Luteinizing Hormone) | 6.9 miu/ml | ±3.94 |
| Estradiol | 73.6 pg/ml | ±28 |

Table 1 shows the distribution of different biomarkers at the basal level (D3) among the 86 subfertile patients. Results are expressed as mean \pm SD.

| Table 2: Distribution of | of Biomarkers at | Basal Level | (\mathbf{D}_2) among | different age | groups of study | subjects i | (n=86) |
|--------------------------|------------------|-------------|------------------------|---------------|-----------------|------------|----------|
| Lable 2. Distribution | of Diomarkers at | Dasar Lever | (D3) among | uniterent age | groups or study | subjects | (n - 00) |

| | Age Groups | | | | | | |
|-----------------------------------|---------------------------|---------------------------|---------------------------|---------------------------|--|--|--|
| Name of Variables (Mean±SD) | 21-30 years (n=26) | 31-35 years (n=20) | 36-40 years (n=21) | 41-45 years (n=20) | | | |
| AMH | 3.91±3.4 | 3.07±4.5 | 1.87±2.8 | $1.25{\pm}2.6$ | | | |
| FSH | 4.84±2 | 5.18 ± 3.5 | 5.32±2.9 | 9.85±5 | | | |
| LH | 6.88±3.7 | 6.17±4.2 | 5.9±3 | 9.03±4.2 | | | |
| Estradiol | 80.7±19.6 | 68.3±23.4 | 77.5±36.2 | 66.82±30 | | | |

Table 2 shows the mean \pm SD value of different biomarkers among the four age groups of patients. There was a gradual linear decline of AMH observed with an increment of age. The mean value of FSH and LH gradually increased in the higher age groups of 40-45 years than in the lower age group of 21-30 years. Estradiol levels also decreased in a higher age group than in younger age group patients.

| Table 3: Distribution of BM | I among different age gi | roups of study subjects (n=86) |
|-----------------------------|--------------------------|--------------------------------|
|-----------------------------|--------------------------|--------------------------------|

| Age Groups | BMI (Mean ± SD) |
|------------------------------|-----------------|
| 21-30 years (n=25) | 25.2±3.8 |
| 31-35 years (n=20) | 24±3.6 |
| 36-40 years (n=21) | 25.6±3 |
| 41-45 years (n=20) | 25±3.2 |

Table 3 revealed the mean BMI levels of different age groups. It was observed that the mean BMI levels were almost similar in all age groups, and no remarkable difference could be discerned.

| Table | 4. | Correlation (| of age | with Rase | l level | of serum | AMH | FSH | IН | and Estradiol | (Pearson's | Correlati | on) |
|-------|----|---------------|--------|-----------|---------|-----------|------|------|-----|---------------|------------|-----------|------|
| rable | 4: | Conclation | or age | with Dasc | I level | of seruin | AMR. | гоп, | ∟п, | and Estration | (realson s | Conciati | 011) |

| Variables | $\mathbf{Mean} \pm \mathbf{SD}$ | r | P Value | Inference |
|-----------|---------------------------------|-----|---------|-----------------|
| AMH | 2.72±3.61(ng/ml) | 23 | .03 | Significant |
| FSH | 6.20±3.95(miu/ml) | .43 | .000 | Significant |
| LH | 6.97±3.94(miu/ml) | .16 | .141 | Not Significant |
| Estradiol | 73.6±28.07(pg/ml) | 12 | .250 | Not Significant |
| | | | | |

Correlation is significant at the 0.05 level (2-tailed).

Using Pearson's correlation test, the correlation between age and basal level of different serum parameters was observed. The table revealed a negative correlation between age and serum AMH (r=-0.23), and this negative correlation was statistically significant at a 0.03 level P-value. Serum FSH showed a positive correlation (r=0.43) with age, which was statistically significant (p<0.01). Serum LH had a positive correlation and Estradiol had a negative correlation with age, but they were not statistically significant.

| Table 5: Correlation of basal level (D3) of serum AMH with basal | level (D3) of serum FSH, LH, and Estradiol |
|---|--|
| among subfertile patients (Pearson's | Correlation). |

| | 0 | 1 | | , | |
|-----------|---------|-------------|-----------------|-----------------|--|
| | | FSH | LH | Estradiol | |
| AMH | r | 243 | .149 | .121 | |
| | P value | .02 | .170 | .275 | |
| Inference | | Significant | Not Significant | Not Significant | |
| | | | | | |

Correlation is significant at the 0.05 level (2-tailed).

Table 5shows a significant negative correlation between the basal level of serum AMH with serum FSH and a non-significant positive correlation of AMH with LH and Estradiol.

V. Discussion

The purpose of this cross-sectional observational study was to determine the mean serum AMH levels in infertile patients and to assess any observable relationship between age and serum AMH levels with other reproductive biomarkers such as FSH, LH, and Estradiol. AMH, or anti-Mullerian hormone, is a dimeric glycoprotein that is made up of two monomers connected by disulfide bonds and belongs to the transforming growth factor β superfamily.^[20] Early follicular Anti Mullerian hormone is a novel ovarian reserve indicator. A large number of studies have been conducted to investigate the relationship between age and serum AMH.^{[20]-} ^[23]In the current study, the mean AMH at the basal level was 2.72 ng/ml. In our study, biomarkers of various variables (AMH, FSH, LH, Estradiol) were measured in participants of various ages. The participants were divided into four age groups: 21-30 years old (n=25), 31-35 years old (n=20), 36-40 years old (n=21), and 41-45years old (n=20). Among these four subgroups, it was discovered that mean AMH levels decreased slightly in the first two age groups but significantly in the last two. Mean FSH levels increased slightly in the first three age groups but dramatically in the final age group of 41-45 years. Mean LH levels decreased between the ages of 31 and 40 but increased dramatically among participants aged 41 to 45. The mean Estradiol level did not consistently increase or decrease across all four age groups. The difference in AMH levels between age groups was statistically significant. Our research also discovered a significant drop in AMH levels after the age of 35. The mean value of AMH in the 35-40-year age group was 1.872.8 ng/ml. This finding was consistent with another study by Singer and Barad et al, which found a significant decrease in AMH above the age of 35, but no significant increase in FSH.^[24] They discovered that the mean level of AMH in the age group 35 was 2.02.4 ng/mL, 1.40.7 ng/mL in the age group 35-37, and.8ng/mL in the age group 38-40. Other studies concluded that both AMH and FSH were probably at their best in reflecting ovarian function at the age of 35.^{[25],[26]} Our analysis confirmed that basal AMH and basal FSH have a significant negative and positive correlation, i.e., AMH decreases with advanced female age while FSH increases. The day 3 FSH level was the old standard for ovarian reserve testing. Every lab uses a different scale to determine what a normal FSH cut-off value is for indicating a successful pregnancy. FSH levels below 10miu/ml (10) are considered normal, while levels above 10miu/ml (>10) are considered abnormal for a female during her reproductive years.^[27] Our research found a significant positive correlation between age and FSH basal levels. The increase in FSH level (9.034.2) is more pronounced in women aged 41-45 years than in the other three age groups studied in this study. This was consistent with the findings of other studies.^[28] Our study found that the age group 41-45 years had a significantly higher basal level of LH than the age groups 21-30 years and 31-35 years. Shin et al., on the other hand, discovered that serum levels of E2, LH, and inhibin B did not differ significantly by age group.^[29] Their research also found that serum LH was higher and inhibin was lower in women in their 40s than in women in their 20s and 30s. The current study's basal LH also shows a weak positive correlation with age and AMH, but no significant association.

Limitations of The Study

The study was conducted in a single hospital with a small sample size. So, the results may not represent the whole community.

VI. Conclusion

According to our findings, the AMH level decreases with age. Serum AMH was found to be negatively correlated with age, while serum FSH was found to be positively correlated with age. Age had a weak positive correlation with LH and a very weak negative correlation with estradiol, neither of which was statistically significant. Serum AMH and FSH had a significant inverse relationship. There was also a significant difference in mean serum AMH levels between age groups.

Funding: No funding sources

Conflict of interest: None declared

Ethical approval: The study was approved by the Institutional Ethics Committee

References

- [1]. Templeton A, Fraser C & Thrompton B (1990) The epidemiology of infertility in Aberdeen. Br Med J 301, 142-52.
- [2]. Evers JLH (2002) Female Subfertility. The Lancet 360,151-159.
- [3]. Roudebush WE, Kivens WJ, Mattke JM (2008) Biomarkers of Ovarian Reserve. Biomarker Insights; 3: 259-268 available from http:// creativecommons.org/licences/by/3.0, visited on 2011, October 26.
- [4]. Kumar P, Malhotra N (2008) Jeffcoates Principles of Gynaecology.7th International edition. :pp699,700.New Delhi: Joypee Brothers Medical Publishers.
- [5]. Edmonds D K (2006) Dewhurst's Textbook of Obstetric & Gynaecology,7TH edition Blackwell Publishing: pp-440,441.
- [6]. Baird DT, Collins J, Egozcue J, Evers LH, Gianaroli L, Leridon H, Sunde A, Templeton A, Steirteghem AV et al. (2005) Fertility and aging. Hum Reproduction Update 11, No-1, 261 -267.
- [7]. Greenseid K, Jindal S, Zapantis A, Nihsen M, Hurwitz J, Paul L (2009) Declining ovarian reserve Adversely influences granulose cell viability. Fertil Steril 91 No-6, 2611-2615.
- [8]. Lenton EA, Landgren BM, Sexton L, Herper R (1984) Normal variation in the length of the follicular phase of the menstrual cycle: effect of chronolocal age. Br J Obstet Gynecol 91, 681-684.
- [9]. Lee MM, Donahhoe PK, Hasegawa T, Silverman B, Crist GB, Best S, Hasegawa Y, Noto RA, Schoenfeld D, Maclaughlin DT (1996). Mullerian inhibiting substance in human: normal levels from infancy to adulthood. J Clin Endocrinol Metab 81(2), 571-6.
- [10]. Cate RL, Mattaliano RJ, Hession C, Tizard R, Farber NM, Cheung A et al (1984) Isolation of the bovine and human genes for Mullerian inhibiting substance and expression of the human gene in animal cells. Cell 45, issue 5,6 June. 685-698.
- [11]. La Marca A, Volpe A (2006) Anti-mullerian hormone(AMH) in female reproduction: is measure measurement of circulating AMH a useful tool? Clinical Endocrinology 64, 603-610
- [12]. Durlinger AL, Kramer P, Karel B, de Jong FH, Uilenbroek JT, Grootegoed JA, Themmen AP (1999)Control of primordial follicle recruitment by Anti-Mullerian hormone in the mouse Ovary. Endocrinology 140, 5789-5796.
- [13]. Durlinger AL, Visser JA, Themmen AP (2002) Regulation of ovarian function: the role of anti-mullerian hormone. Reproduction 124, 601-609.
- [14]. Weenen C, Laven JSE, von Bergh ARM, Cranfield M, Groome NP, Visser JA et al (2004) Anti-Mullerian hormone expression pattern in the human ovary: potential implications for Initial and cyclic follicle recruitment. Molecular Human Reproduction 10 No.2, 77-83.
- [15]. Advanced Fertility Centre of Chicago. Anti-Mullerian Hormone Testing of Ovarian Reserve available on www.advanced fertility.com/amh-fertility test.html visited on 2011 Oct 26.
- [16]. Te Velde ER and Pearson PL (2002) The variability of female reproductive age. Hum Reproduction Update 8 No.2, 141-154.
- [17]. De Vet A, Laven JS, de Jong FH, Themmen AP, Fauser BC (2002) Anti-Mullerian hormone levels : a putative marker for ovarian aging. Fertil Steril 77, 357-362.
- [18]. Van Rooij IA, Broekmans FJM, Scheffer GJ, Looman CWN, Habbema JDF, de Jong FH, Fauser BJCM, Themmen AP, Te Velde ER (2005) Serum Anti-Mullerian hormone levels best reflect the reproductive decline with age in normal women with proven fertility: a longitudinal study. Fertil Steril 83, 979-987.
- [19]. Meduri G, Massin N, Guibourdenche, Bachelot A, Fiori O, Kuttenn F, Misrahi M, Touraine P (2007) Serum anti-Mullerian hormone expression in women with premature ovarian failure. Hum Reproduction 22 No-1, 117-123.
- [20]. La Marca A, Sighnolfi G,Radi D, Argenti C, Baraldi E,Artenisio AC, Volpe A (2009) Anti-Mullerian hormone (AMH) as a predictive marker in assisted reproductive technology(ART)', Human Reproduction Update 16 No 2, 113-130
- [21]. Feyerisen E,Ficicioglu C, Kultu M,Baglam E, Bakacak Z (2006) Early follicular antimullerian hormone as an indicator of ovarian reserve. Fertil Steril 85, 592-596.
- [22]. Visser JA, JD, de Jong FH, Laven JS, Themmen AP (2006) Anti-Mullerian hormone a new marker for ovarian function. Reproduction 131, 1-9.
- [23]. Van Rooij IA, Broekmans FJ, Scheffer GJ, Te Velde ER. FauserBJ, Bancsi LF, JD, de Jong FH, Themmen AP (2002) Serum anti-Mullerian hormone levels : a novel measure of ovarian reserve. Hum Reprod 283, 1415-1421.
- [24]. Singer T, Barad DH, Weghfer A, Gleicher N (2009) Correlation of antimullerian hormone and baseline follicle stimulating hormone levels. Fertility and Sterility 91(6), 2616-2619
- [25]. Gleicher N, Weghofer A, Barad DH (2011) Defining ovarian reserve to better understand ovarian aging Reproductive Biology and Endocrinology 9, 23 http://www.rbej.com/content
- [26]. Barad DH, Weghofer A, Gleicher N (2011) Utility of age specific serum anti-Mullerian hormone concentrations. Reproductive Bio Medicine Online 22,284-291.
- [27]. Muttukrishna, S., Suharjono, H., McGarrigle, H. and Sathanandan, M., 2004. Inhibin B and anti- Mullerian hormone: markers of ovarian response in IVF/ICSI patients?. BJOG: An International Journal of Obstetrics & Gynaecology, 111(11), pp.1248-1253.
- [28]. Schipper, I., De Jong, F.H. and Fauser, B.C., 1998. Lack of correlation between maximum early follicular phase serum follicle stimulating hormone concentrations and menstrual cycle characteristics in women under the age of 35 years. Human reproduction (Oxford, England), 13(6), pp.1442-1448.
- [29]. Shin, S.Y., Lee, J.R., Noh, G.W., Kim, H.J., Kang, W.J., Kim, S.H. and Chung, J.K., 2008. Analysis of serum levels of anti-Müllerian hormone, inhibin B, insulin-like growth factor-I, insulin-like growth factor binding protein-3, and follicle-stimulating hormone with respect to age and menopausal status. Journal of Korean medical science, 23(1), pp.104-110.

Dr. Rumana Sultana, et. al. "Association of Age and Serum Anti-Mullerian Hormone level with Serum FSH, LH, and Estradiol." *IOSR Journal of Dental and Medical Sciences (IOSR-JDMS)*, 21(11), 2022, pp. 20-24.

DOI: 10.9790/0853-2111082024